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A B S T R A C T
The majority of marketed drugs remain understudied in some patient populations such as pregnant women,
paediatrics, the obese, the critically-ill, and the elderly. As a consequence, currently used dosing regimens may
not assure optimal eﬃcacy or minimal toxicity in these patients. Given the vulnerability of some subpopulations
and the challenges and costs of performing clinical studies in these populations, cutting-edge approaches are
needed to eﬀectively develop evidence-based and individualized drug dosing regimens. Five key issues are
presented that are essential to support and expedite the development of drug dosing regimens in these
populations using model-based approaches: 1) model development combined with proper validation procedures
to extract as much valid information from available study data as possible, with limited burden to patients and
costs; 2) integration of existing data and the use of prior pharmacological and physiological knowledge in study
design and data analysis, to further develop knowledge and avoid unnecessary or unrealistic (large) studies in
vulnerable populations; 3) clinical proof-of-principle in a prospective evaluation of a developed drug dosing
regimen, to conﬁrm that a newly proposed regimen indeed results in the desired outcomes in terms of drug
concentrations, eﬃcacy, and/or safety; 4) pharmacodynamics studies in addition to pharmacokinetics studies for
drugs for which a diﬀerence in disease progression and/or in exposure-response relation is anticipated compared
to the reference population; 5) additional eﬀorts to implement developed dosing regimens in clinical practice
once drug pharmacokinetics and pharmacodynamics have been characterized in special patient populations. The
latter remains an important bottleneck, but this is essential to truly realize evidence-based and individualized
drug dosing for special patient populations. As all tools required for this purpose are available, we have the
moral and societal obligation to make safe and eﬀective pharmacotherapy available for these patients too.
1. Introduction
Patients included in clinical trials during drug development are
selected based on strict inclusion and exclusion criteria. Consequently,
for the majority of drugs on the market, eﬃcacy and safety are
understudied and poorly characterized in various patient subpopula-
tions, including pregnant women, paediatrics, the obese, the critically-
ill, and the elderly. As a result, dosing regimens are not selected for
optimal eﬃcacy or minimal toxicity in these patients.
Evidence-based and individualized drug dosing regimens are tai-
lored to individual needs by accounting for patient and treatment
characteristics that inﬂuence the pharmacokinetics and pharmacody-
namics of drugs. Trials needed to develop such dosing regimens are
challenging, due to a myriad and ever changing landscape of rules and
regulatory restrictions, and they are expensive to perform in all special
patient populations. Therefore, approaches have been developed to
expedite the development of evidence-based and individualized drug
dosing regimens for these populations. Here we discuss ﬁve key issues
regarding model-based approaches that are important to consider in
this respect. These approaches have been successfully applied in the
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paediatric population, the critically-ill, and obese patients, and can be
extended to other special patient populations.
2. Population modeling
Special patient populations are often smaller than reference popula-
tions. Especially in children, practical and ethical constraints also limit
the number of patients that can be included in studies as well as the
number of invasive samples that can be obtained per patient. Moreover,
studies in special populations are generally performed during routing
clinical practice, which may negatively impact the information content
of the obtained data. As a result, data obtained in special patient
populations requires advanced methods with increased ﬂexibility and
statistical power to obtain a suﬃciently high level of evidence from
these data to derive drug dosing regimen.
Population modeling, also known as non-linear mixed eﬀects
modeling, is ideally suitable to study drug pharmacology in special
patient populations (Admiraal et al., 2014; De Cock et al., 2011). This
approach is based on the simultaneous analysis of pharmacological
outcome data from multiple individuals and characterizes drug phar-
macokinetics and/or pharmacodynamics on a population level, while
also quantifying inter-individual variability. The quantiﬁcation of inter-
individual variability allows subsequent identiﬁcation of patient-spe-
ciﬁc or treatment-speciﬁc predictors that can (partially) contribute to
observed diﬀerences in drug exposure or exposure-response relation-
ships in the studied population. These so-called covariates can serve as
the basis for individualized drug treatment.
As population models for special patient populations are generally
based on limited observations, the risk of drawing wrong conclusions is
substantial. Therefore, although often overlooked (Brendel et al., 2007;
Tod et al., 2008), the statistical validation of outcome predictions by
models is essential before model-derived dose regimens can guide
individualized pharmacotherapy. These statistical model validations
should include at least an extensive internal validation, comparing
model predictions to the observations used for model building
(Admiraal et al., 2014; Krekels et al., 2011; Nguyen et al., 2016). An
external validation, comparing model predictions to new external
observations is also essential to perform. External data can be obtained
in new clinical trials, but to limit resources and reduce the burden to
patients, historic data or opportunistic samples may also be used for this
purpose although the latter by nature are less reliable (Ince et al., 2009;
Krekels et al., 2011).
Since study and patient characteristics in some populations may
diﬀer from those in traditional clinical trials, it is important to tailor the
statistical model validation procedures to these characteristics (Krekels
et al., 2011). It has for instance been shown that inapt validation of a
published paediatric model for the pharmacokinetics of morphine failed
to identify misspeciﬁcation of the covariate model, resulting in a
systematic under-prediction of morphine and metabolite concentrations
in neonates and infants, which could have led to a disastrously high
doses in these patients, in case that model had been used for dose
predictions (Krekels et al., 2011).
3. Integration of data and use of prior pharmacological and
physiological knowledge
As mentioned, the potential sample size of patients is limited in
special patient populations. Moreover, the heterogeneity in these
populations increases noise in the data, while the vulnerability of many
sub-populations may limit the amount of invasive samples that can be
obtained per patient. In addition to costs, these factors may consider-
ably limit the feasibility of dedicated trials for each relevant drug in
special patient populations. To cope with this limited data potential,
strategies should be applied to most optimally use existing data and
prior knowledge, both for study design, data analysis and the identi-
ﬁcation of drug-speciﬁc and system-speciﬁc properties.
For many drugs, historic data or scavenged samples are available in
various research groups. Such data could be used for either initial
model building and to optimize study designs, or for the external
validation of models. Diﬀerences in study protocols or analytical
methods do not hamper a population analysis of pooled data, although
diﬀerences in data recording may require additional harmonization of
data. Furthermore, issues regarding patient consent, conﬁdentiality,
and proprietary claims, require strict agreements and a secure infra-
structure for data handling and data storage (Ince et al., 2009). The
Mechanism-Based PK-PD Modeling Platform within the Dutch Top
Institute Pharma is a distinctive example of successful eﬀorts to share
data between multiple research groups in both academia and pharma-
ceutical industry (http://www.tipharma.com/pharmaceutical-research-
projects/completed-projects/pk-pd-modeling-platform.html).
As demonstrated extensively for the paediatric population, oppor-
tunistic or scavenged samples and therapeutic drug monitoring (TDM)
data can be valuable sources of information on patient subpopulations
(Allegaert et al., 2008; Autmizguine et al., 2014; Gonzalez et al., 2014;
Leroux et al., 2015a; Zhao et al., 2015). Even when these samples
cannot be used to inform a full population model, they may be useful in
the presence of more informative data from a reference population, to
inform the covariate model for the special patient population and also
allow model-based predictions in that population (Voller et al., in
preparation).
Despite initiatives on data sharing or opportunistic sampling, the
need for dedicated studies in special populations will never be negated.
Software tools for simulations and optimal study design can be used to
optimize sampling strategies based on prior knowledge or limited
existing data, so that samples containing most information on the
endpoint of interest can be obtained during clinical studies with a
minimal burden to individual patients (Ince et al., 2009; Nyberg et al.,
2015; Van Hasselt et al., 2013, 2014). Involvement of a pharmacome-
trician familiar with these techniques during study design is therefore
of high value.
Another important strategy to cope with the limited data potential is
increasing the information derived from study data through the
integration of ﬁndings regarding drug pharmacology and patient
physiology. Population models are empirical models yielding informa-
tion on particular drugs in particular populations. The potential to
extrapolate ﬁndings from one drug to another drug in the same
population, or from one population to another population for the same
drug, is restricted. This results from the fact that parameters in
population models contain both system-speciﬁc and drug-speciﬁc
information.
Currently several research eﬀorts are focused on developing meth-
odologies to disentangle system-speciﬁc information from drug-speciﬁc
information, using for instance physiology-based pharmacokinetic
modeling or systems pharmacology models (Danhof, 2016). Only when
system-speciﬁc and drug-speciﬁc information are disentangled for a
certain drug in a certain population, can extrapolations be made to
inform on the pharmacology of other drugs or other populations. For
example, a population analysis on the pharmacokinetics of midazolam
showed systemic clearance of this drug to be similar in obese patients
undergoing bariatric surgery and healthy volunteers, while oral bioa-
vailability was lower in the bariatric patients (Brill et al., 2014a,
2014b). One year after surgery and considerable subsequent weight
loss, systemic midazolam clearance in the patients had increased
statistically signiﬁcantly, whereas oral bioavailability remained un-
changed (Brill et al., 2015). To better understand the physiological
basis of these ﬁndings a physiology-based pharmacokinetic model was
developed for midazolam and its hydroxymetabolite in the bariatric
patients before and after weight loss, with speciﬁc focus on the CYP3A
activity in the gut wall and liver. From this it could be concluded that
hepatic metabolic clearance of midazolam increases after weight loss,
while metabolic clearance in the gut wall is low and highly variable
both before and after weight loss (Brill et al., 2016). After obesity-
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related changes in hepatic blood ﬂow and perfusion have been
elucidated, the information obtained in this analysis can be used to
predict systemic and pre-systemic clearance of other CYP3A substrates
based on drug-speciﬁc properties.
An advantage of physiology-based pharmacokinetic models in the
previous example is that the system-speciﬁc information mostly com-
prises quantiﬁable physiological parameters that only need to be
obtained once. However, these models do require a wealth of informa-
tion that is currently not available for each subpopulation. Therefore
faster and less data-intensive methods are also being investigated for
the integration of knowledge on physiology and drug pharmacology. It
has for instance been hypothesized that covariate relationships in
paediatric pharmacokinetic models reﬂect the net inﬂuence of all
changes in the physiological processes underlying particular pharma-
cokinetic processes. If this were true, it should be possible to extra-
polate paediatric covariate relationships for clearance from one drug to
another that is eliminated through the same pathway. Although this has
indeed been conﬁrmed for some drugs, including drugs eliminated
through glomerular ﬁltration and drugs undergoing glucuronidation
(De Cock et al., 2014a, 2014b; Krekels et al., 2012a, 2012b), recent
ﬁndings show that these extrapolations should be used carefully.
Indeed, it was found that properties of both the model drug and the
target drug inﬂuence the extrapolation potential of covariate relation-
ships, with the extraction ratio of both drugs being especially predictive
(Calvier et al., 2014). Similar research also showed that drug properties
inﬂuence the predictive properties of allometric scaling in the paedia-
tric population (Calvier et al., 2016). As the user-friendliness makes
these relatively simple approaches attractive, more research is needed
to explore in which situations extrapolations are justiﬁed.
4. Prospective evaluation of model-derived drug dosing regimens
To implement model-derived dosing regimens in clinical practice, it
is essential to perform a prospective clinical study that evaluates the
drug concentrations as well as eﬃcacy and safety proﬁles obtained with
the newly proposed dosing regimen as proof of principle. Only after
expected clinical outcome parameters have been conﬁrmed, should a
dosing regimen be implemented in clinical practice (Ince et al., 2009).
Prospective clinical studies may reveal new information that could
not be derived from data from studies performed with former dosing
regimens. Non-linearities in pharmacokinetics or physiological re-
sponses may for example yield unexpected outcomes with previously
untested drug doses. Moreover, prospective studies may reveal addi-
tional factors contributing to inter-individual variability in drug
responses that were not taken into account in the developed regimen.
For instance for morphine, when a model-derived dosing regimen
correcting for diﬀerences in the pharmacokinetics of this drug across
a population of newborns and young infants was prospectively eval-
uated, it was revealed that age-related diﬀerences in sensitivity to pain
and/or morphine concentrations were an additional cause for age-
related diﬀerence in required rescue medication (Ceelie et al., 2013;
Krekels et al., 2014). This prospective study conﬁrmed that corrections
for diﬀerences in pharmacokinetics yield improvement of the pharma-
cotherapy particularly for the youngest neonates who required much
lower dosages. Yet it also emphasizes that further pharmacodynamic
studies are required to identify age-appropriate morphine target con-
centrations for older infants.
This example illustrates that when untested dosing regimens are
evaluated in prospective clinical studies, it is advisable to monitor
patients and allow for protocol deviations, including dose adjustments,
when necessary. Such dose adjustments can be guided by directly
observable outcome measures or, if these are not available, by proxies
like TDM. In a currently ongoing study on a new paediatric dosing
regimen for anti-thymocyte globulin derived from detailed studies on
the pharmacokinetics (Admiraal et al., 2015b) and pharmacodynamics
(Admiraal et al., 2015a) in children, TDM is being performed to avoid
unexpected under- or over-exposure, resulting from the considerable
changes in the new regimen.
5. Drug dosing based on pharmacokinetics and
pharmacodynamics
Special patient populations may deviate from the reference patient
population included in clinical trials regarding both pharmacokinetics
and pharmacodynamics. The latter may cover both desired eﬀects and
side-eﬀects. Much pharmacological research in special patient popula-
tions has however focused on the pharmacokinetic diﬀerences only.
In a number of cases, dose regimens that correct only for inter-
individual diﬀerences in pharmacokinetics may indeed suﬃce. The FDA
has developed a decision tree to guide pharmaceutical industry on the
requirements for paediatric clinical studies during drug development
(http://www.fda.gov/ScienceResearch/SpecialTopics/
PediatricTherapeuticsResearch/ucm106614.htm), that can be extended
to other special patient populations as well. According to this decision
tree, pharmacokinetic bridging studies suﬃce if the following criteria
are met: 1) the special patient population and reference population can
reasonably be assumed to have similar disease progression and similar
response to intervention, and 2) the exposure-eﬀect relationship
between the special patient population and reference population can
be assumed to be the same for the drug of interest.
Antibiotics or antivirals for the treatment of infectious diseases are
examples of drugs that are likely to meet these criteria. For pharma-
cokinetic bridging to work, it is imperative to study the pharmacoki-
netics at the relevant target site or a site that accurately reﬂects
concentrations at this target site. It has for instance been shown that
obese patients reach much lower subcutaneous tissue levels of cefazolin
than their non-obese counterparts at the same serum concentrations. As
this drug is intended to act in subcutaneous tissue to prevent post-
operative wound infections, obese patients therefore require higher
doses and higher serum concentrations for adequate prophylaxis (Brill
et al., 2014a, 2014b).
The previous example of morphine suggests that in the paediatric
population morphine does not meet the FDA criteria for bridging
pharmacokinetic only. It can for instance be imagined that receptor
expression or signal transduction for both pain and morphine are age-
dependent. Alternatively, transport of morphine from plasma to the
brain may be age-dependent (Lam et al., 2015). In these cases,
pharmacodynamics studies using validated clinical endpoints in the
pertaining patient population are essential to determine appropriate
target concentrations in diﬀerent subpopulations.
A number of pharmacodynamic studies have shown treatment
indication or disease severity to be potentially important pharmacody-
namic covariates that need to be taken into account for optimal drug
dosing. A study in neonates with necrotizing enterocolitis (NEC)
indicated increased morphine dose requirements compared to post-
operative patients. This may results from prolonged and former pain
experienced by NEC patients (Meesters et al., 2016), or from diﬀerences
in the pain stimuli. Additionally, for the treatment of critically-ill adult
patients it was found that the sensitivity to propofol sedation increased
with increasing Sequential Organ Failure Assessment (SOFA) scores,
suggesting that target concentrations for propofol decrease consider-
ably with increasing disease severity (Peeters et al., 2008).
In addition to the pathophysiological and pharmacological require-
ments mentioned above, accurate bridging of ﬁndings between patient
subpopulations requires the same endpoints in both populations. This
may not be the case for drugs used for the treatment of outcomes that
are quantiﬁed based on self-report. Ideally, surrogate endpoints that
can be used as alternatives in such cases are biomarkers that can be
directly and objectively measured. When such endpoints are not
available, as is the case for pain, ratings by caregivers are often used
in non-verbal populations, like the COMFORT-B scale in paediatric
patients (Ista et al., 2005) or the REPOS scale in non-communicative
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adults and cognitively impaired elderly (van Herk et al., 2009). For
these endpoints it is essential that they are validated to be appropriate
in the particular patient population before using them to investigate the
pharmacodynamics of a drug.
Ratings by caregivers are often based on questionnaires and scales
containing multiple items. It has been shown that advanced data
analysis techniques can improve the statistical power of identifying
drug eﬀects in studies using these scales. Based on composite
COMFORT-B scores, it was for instance not possible to support
morphine treatment over placebo in neonates on artiﬁcial ventilation
(Simons et al., 2003), but re-analyses using item response theory
showed statistically signiﬁcant beneﬁts of morphine (Välitalo et al.,
Accepted). Furthermore, advanced statistical methods can be applied to
increase the information content of scores from multi-item scales. Item
response theory for instance also revealed which sub-items in the
COMFORT and PIPP scale are most speciﬁc for pain and best reﬂect
changes in pain behavior in neonates (Välitalo et al., 2016).
6. Clinical implementation of ﬁndings
Once evidence-based and individualized dosing regimens are avail-
able from validated models and following conﬁrmation of the desired
outcome in a prospective clinical trial, the dosing regimens need to be
implemented in clinical practice, for which careful guidance is para-
mount.
To date, the clinical implementation of evidence-based drug dosing
in special patient populations is still limited. For antibiotics treatment
in the paediatric population, a recent study identiﬁed 444 diﬀerent dose
regimens for 41 diﬀerent antibiotics in France (Leroux et al., 2015b).
Similarly, for vancomycin dosing and TDM, 24 diﬀerent protocols were
identiﬁed in the UK (Kadambari et al., 2011). While an evidence-based
regimen has been identiﬁed for vancomycin (Janssen et al., 2016),
gentamicin and tobramycin (Valitalo et al., 2015), these regimens have
not yet been fully included in (inter)national formularies. Successful
examples in this respect are the adjustment of cefazolin prophylaxis
doses for obese subpopulations which are to be implemented in Dutch
SWAB guidelines as well as model-derived amikacin dosing in neonates
(Smits et al., 2015) which is implemented in Leuven neonatal ICU and
in the Dutch paediatric formulary.
Finally, it is important to mention, that pharmacokinetic or
pharmacodynamic covariates may not always be suﬃcient to support
individualized dosing regimen, meaning that additionally monitoring
may still be warranted for some drugs. Besides standard monitoring for
safety and eﬃcacy, especially for drugs with a relatively high unex-
plained variability in pharmacokinetics or pharmacodynamics and a
small therapeutic window, TDM may remain necessary. This has for
instance been the case for busulfan in the treatment of paediatric
haematopoietic stem cell transplantation patients where model-derived
improvements in doses have been proposed (Bartelink et al., 2012). In
these cases, TDM remains relevant to mitigate random unexplained
variability, but optimized dosing regimens can improve the selection
for the ﬁrst dose thereby reducing the need for dose adjustments upon
TDM.
7. Summary
While it remains challenging to develop evidence-based and in-
dividualized dosing regimens for special patient populations, the
knowledge and tools to do so are available. We therefore have an
obligation to make safe and eﬀective pharmacotherapy available for
these patients. Current eﬀorts in integrating research information and
further increasing statistical power of pharmacodynamic scales and
data analysis techniques will help this ﬁeld move forward even further.
To date, it seems that implementation of ﬁndings in clinical practice
still remains one of the biggest challenges that requires sustained
eﬀorts.
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